Education · Tier 5

· Last Reviewed May 15, 2026· PSI Editorial Board· Independent

What Injection Routes Are Used for Peptide Therapy?

The conceptual reference for FDA-approved peptide therapy injection routes anchored in FDA prescribing information and AMA Code of Medical Ethics 1.1.5.

FDA-approved peptide therapy uses three primary injection routes.

The routes are subcutaneous, intramuscular, and intravenous.

The specific route is determined by the FDA label for each peptide drug.

3 Routes

Primary Injection Routes

Subcutaneous (SC), intramuscular (IM), and intravenous (IV) routes across FDA-approved peptide therapy

SC Most

Common Route

Subcutaneous administration is the most common route across FDA-approved peptide drugs

FDA Label

Route Determined

The specific injection route is determined by the FDA label for each FDA-approved peptide drug

Physician

Required Decision

The physician determines dosing, route, schedule, and clinical context per FDA prescribing information

Quick Answer

FDA-approved peptide therapy uses three primary injection routes. The routes are subcutaneous, intramuscular, and intravenous. This page provides conceptual education only and does not provide specific dosing or self-administration instructions.

Subcutaneous administration delivers medication into the subcutaneous tissue layer beneath the skin. The route is the most common across FDA-approved peptide drugs. The GLP-1 receptor agonist class uses subcutaneous administration. Examples include Semaglutide (Wegovy NDA 215256, Ozempic NDA 209637) and Tirzepatide (Zepbound NDA 217806, Mounjaro NDA 215866). The anabolic osteoporosis peptide class uses subcutaneous administration. Examples include Teriparatide (Forteo NDA 021318) and Tesamorelin (Egrifta NDA 022505).

Intramuscular administration delivers medication into muscle tissue. The route is used for some FDA-approved peptide drugs including Evenity romosozumab (NDA 761062 with cardiovascular boxed warning). The route is also used for Vyleesi bremelanotide (NDA 210557 for HSDD in premenopausal women) which uses subcutaneous administration per FDA label.

Intravenous administration delivers medication directly into the venous system. The route is used in inpatient and clinic-administered contexts for specific peptide therapy indications.

The physician determines dosing, route, schedule, and clinical context per FDA prescribing information. AMA Code of Medical Ethics 1.1.5 governs off-label and compounded prescribing decisions. See Compounded vs FDA-Approved Peptides for the regulatory pathway distinction. See Peptides 101 for the broader framework.

This page is conceptual education only. Dosing, route selection, and administration instruction must be provided by a qualified physician evaluating your individual situation.

Subcutaneous administration is the most common route across FDA-approved peptide drugs. The GLP-1 receptor agonist class uses subcutaneous administration. The anabolic osteoporosis peptide class uses subcutaneous administration. The physician determines the appropriate route, schedule, and clinical context per FDA prescribing information. AMA Code of Medical Ethics 1.1.5 governs off-label and compounded prescribing decisions. This page provides conceptual education only. Dosing and administration must be determined by a qualified physician.

INJECTION PROTOCOLS REFERENCE

At a Glance: Injection Protocols 101

Route / Framework	Subtitle	Animal Evidence	Human Evidence	Clinical Application
Subcutaneous (SC) route	Delivery into subcutaneous tissue layer beneath the skin	—	Strong	Most common route across FDA-approved peptide drugs. Used for GLP-1 receptor agonists and anabolic osteoporosis peptides. Physician determines clinical context
Intramuscular (IM) route	Delivery into muscle tissue	—	Moderate	Used for some FDA-approved peptide preparations per FDA prescribing information. Physician determines route per FDA label
Intravenous (IV) route	Delivery directly into the venous system	—	Moderate	Used in inpatient and clinic-administered contexts for specific peptide therapy indications. Healthcare provider administration
FDA prescribing information determines route	Each FDA-approved peptide has a label-specified route	—	Strong	Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda use subcutaneous. Forteo, Tymlos use subcutaneous. Evenity uses subcutaneous (two injections per dose)
Compounded preparation framework	AMA Code 1.1.5 governs off-label prescribing	—	Moderate	Compounded peptide preparations operate under FDA Compounding Quality Act of 2013. Physician documents risk-benefit and FDA-approved alternatives
Four-stage monitoring cadence	Baseline, early follow-up, stabilization, maintenance	—	Strong	Baseline week 0, early follow-up week 4 to 8, stabilization month 3, maintenance month 6 with annual continuation. Physician-directed framework
Adverse event reporting through FDA MedWatch	Surveillance framework for FDA-approved drugs	—	Strong	MedWatch supports serious adverse event reporting across the FDA-approved peptide drug class for ongoing safety signal monitoring
Physician-only administration decisions	Dosing, route, schedule per individual clinical context	—	Strong	FDA labels specify dosing ranges. Physician selects dose, route, and schedule for individual patient. Patient administration guidance from physician only

Six Things You Need to Know About Peptide Injection Routes

This page covers FDA-approved peptide therapy injection route framework in conceptual terms. Section one covers subcutaneous administration as the most common route. Section two covers intramuscular and intravenous routes per FDA prescribing information. Section three covers the four-stage monitoring cadence and AMA Code 1.1.5 framework. Section four covers physician-only administration decisions. This page is conceptual education only.

Subcutaneous Administration Is the Most Common Route

Subcutaneous administration is the most common route across FDA-approved peptide drugs. The route delivers medication into the subcutaneous tissue layer beneath the skin. The GLP-1 receptor agonist class and the anabolic osteoporosis peptide class use subcutaneous administration.

Subcutaneous (SC) administration delivers medication into the subcutaneous tissue layer between the dermis and the underlying muscle. The route supports slower absorption compared to intramuscular or intravenous routes. The slower absorption profile suits many peptide drugs designed for sustained pharmacologic effect. The GLP-1 receptor agonist class uses subcutaneous administration. Examples include semaglutide (Wegovy NDA 215256 for chronic weight management, Ozempic NDA 209637 for type 2 diabetes), tirzepatide (Zepbound NDA 217806 for chronic weight management, Mounjaro NDA 215866 for type 2 diabetes), and liraglutide (Saxenda for weight management, Victoza for type 2 diabetes). The anabolic osteoporosis peptide class uses subcutaneous administration. Examples include teriparatide (Forteo NDA 021318) and abaloparatide (Tymlos NDA 208743). Romosozumab (Evenity NDA 761062 with cardiovascular boxed warning) uses subcutaneous administration via two injections per dose per FDA label. Tesamorelin (Egrifta NDA 022505 for HIV-associated lipodystrophy) uses subcutaneous administration. The physician determines dosing and clinical context per FDA prescribing information. This page provides conceptual education only.

Intramuscular and Intravenous Routes Apply for Specific Indications

Intramuscular (IM) and intravenous (IV) routes apply for specific peptide therapy indications per FDA prescribing information. The routes are used in clinic-administered contexts where healthcare provider administration is appropriate.

Intramuscular administration delivers medication into muscle tissue. The route supports faster absorption compared to subcutaneous administration. The route is used for some peptide preparations per FDA prescribing information and per indication-specific clinical context. Intravenous administration delivers medication directly into the venous system. The route supports immediate availability and precise dose-response control. The route is used in inpatient and clinic-administered contexts for specific peptide therapy indications. Healthcare provider administration of IV peptide therapy occurs in monitored clinical settings. Examples of IV peptide therapy contexts include some hospital-administered peptide preparations and specific diagnostic peptide preparations (such as macimorelin used for adult-onset growth hormone deficiency diagnostic testing per AACE 2019 framework). The physician selects the appropriate route per FDA prescribing information and individual clinical context. The framework operates under AMA Code of Medical Ethics 1.1.5 for off-label and compounded prescribing decisions.

FDA Prescribing Information Determines Route Selection

FDA prescribing information determines the appropriate route for each FDA-approved peptide drug. The label specifies dosing, route, schedule, and clinical context. The physician applies FDA label guidance to individual patient context.

FDA prescribing information for each FDA-approved peptide drug specifies the indicated route of administration. The label includes dosing range, schedule, indication, and clinical context. The label reflects Phase 3 trial evidence supporting the FDA approval. Examples of FDA prescribing information for FDA-approved peptide drugs include Wegovy semaglutide (NDA 215256) prescribing information specifying subcutaneous weekly administration, Ozempic semaglutide (NDA 209637) specifying subcutaneous weekly administration, Zepbound tirzepatide (NDA 217806) specifying subcutaneous weekly administration, Mounjaro tirzepatide (NDA 215866) specifying subcutaneous weekly administration, Forteo teriparatide (NDA 021318) specifying subcutaneous daily administration, Tymlos abaloparatide (NDA 208743) specifying subcutaneous daily administration, Evenity romosozumab (NDA 761062) specifying subcutaneous monthly administration via two injections per dose with cardiovascular boxed warning, Tesamorelin Egrifta (NDA 022505) specifying subcutaneous daily administration for HIV-associated lipodystrophy, and Vyleesi bremelanotide (NDA 210557) specifying subcutaneous on-demand administration for HSDD in premenopausal women. The physician determines individual patient dosing and clinical context per the FDA label.

Compounded Preparations Operate Under AMA Code 1.1.5 Framework

Compounded peptide preparations operate under the FDA Compounding Quality Act of 2013. AMA Code of Medical Ethics 1.1.5 governs off-label and compounded prescribing decisions including documented risk-benefit assessment and FDA-approved alternatives considered.

The FDA Compounding Quality Act of 2013 (Drug Quality and Security Act framework) establishes two compounding categories. The 503A pathway covers traditional compounding pharmacies. The 503B pathway covers FDA-registered outsourcing facilities. Neither category receives FDA pre-market approval for the compounded product. AMA Code of Medical Ethics 1.1.5 (Off-Label and Investigational Use of Pharmaceuticals) framework governs the prescribing decision. The framework requires documented risk-benefit assessment for the specific patient context. The framework requires documented FDA-approved alternatives considered per indication. The framework requires monitoring requirements including baseline labs and follow-up cadence. The framework requires patient understanding through informed consent acknowledgment. AMA Code 2.1.1 establishes the broader informed consent framework. The physician applying AMA Code 1.1.5 framework determines the appropriate compounded peptide preparation, route, schedule, and clinical context for the individual patient. See [The Compounding Pharmacy System](/education/the-compounding-pharmacy-system) for the regulatory framework.

The Four-Stage Monitoring Cadence Applies Across the Class

The four-stage monitoring cadence applies across FDA-approved and compounded peptide therapy. Baseline at week 0 establishes the foundation. Early follow-up at week 4 to 8 tracks tolerability. Stabilization at month 3 captures steady-state. Maintenance at month 6 with annual continuation applies thereafter.

The four-stage monitoring cadence supports systematic peptide therapy management across indications. Stage 1 baseline at week 0 establishes the indication-appropriate marker panel and AMA Code 1.1.5 documentation for compounded contexts. Stage 2 early follow-up at week 4 to 8 tracks tolerability, side effect emergence, and initial pharmacologic response. The window captures GLP-1 receptor agonist gastrointestinal tolerability assessment and other class-specific early signals. Stage 3 stabilization at month 3 captures steady-state pharmacologic response. The window supports dose adjustment decisions and clinical response assessment. Stage 4 maintenance at month 6 with annual continuation thereafter applies the full panel re-check supporting long-term clinical management. The framework anchors physician-directed peptide therapy across the FDA-approved and compounded class. Indication-specific markers re-checked at each stage depend on peptide class per FDA prescribing information or AMA Code 1.1.5 documentation. See [Biomarker Interpretation](/education/biomarker-interpretation) for marker-specific framework.

Physician Determines All Dosing, Route, and Administration Decisions

The physician determines all dosing, route, schedule, and administration decisions per FDA prescribing information for FDA-approved peptides and AMA Code 1.1.5 framework for compounded preparations. Patient administration instruction is provided by the prescribing physician only.

Physician-only administration decisions apply across FDA-approved and compounded peptide therapy. The physician determines the appropriate dose within the FDA label range for FDA-approved peptides. The physician determines the appropriate route per FDA prescribing information. The physician determines the appropriate schedule (weekly, daily, monthly, on-demand, etc.) per FDA label. The physician determines the appropriate clinical context including indication match, comorbidity assessment, concurrent medication review, and contraindication evaluation. For patient-administered subcutaneous injections, the physician or pharmacist provides administration instruction including site selection, injection technique, needle handling, sharps disposal, and rotation principles. The physician monitors for adverse events through clinical follow-up and FDA MedWatch reporting for serious events. AMA Code 1.1.5 framework applies for off-label and compounded prescribing decisions. This page is conceptual education only. Dosing and administration must be determined by a qualified physician evaluating individual patient context. PSI does not provide personalized administration guidance.

Subcutaneous administration: the most common route across FDA-approved peptide therapy

GLP-1 receptor agonist class and anabolic osteoporosis peptide class subcutaneous framework

Subcutaneous administration delivers medication into the subcutaneous tissue layer between the dermis and the underlying muscle. The route supports slower absorption compared to intramuscular or intravenous routes. The slower absorption profile suits many peptide drugs designed for sustained pharmacologic effect. The route is the most common across the FDA-approved peptide drug class.

The GLP-1 receptor agonist class uses subcutaneous administration. Examples include semaglutide (Wegovy NDA 215256 for chronic weight management with subcutaneous weekly administration, Ozempic NDA 209637 for type 2 diabetes with subcutaneous weekly administration), tirzepatide (Zepbound NDA 217806 for chronic weight management, Mounjaro NDA 215866 for type 2 diabetes), and liraglutide (Saxenda, Victoza with subcutaneous daily administration).

The anabolic osteoporosis peptide class uses subcutaneous administration. Examples include teriparatide (Forteo NDA 021318 with subcutaneous daily administration), abaloparatide (Tymlos NDA 208743 with subcutaneous daily administration), and romosozumab (Evenity NDA 761062 with cardiovascular boxed warning and subcutaneous monthly administration via two injections per dose). Tesamorelin (Egrifta NDA 022505 for HIV-associated lipodystrophy) uses subcutaneous daily administration. The physician determines dosing and clinical context per FDA prescribing information.

Intramuscular and intravenous routes: clinic-administered and indication-specific contexts

Healthcare provider administration framework for specific peptide therapy indications

Intramuscular (IM) administration delivers medication into muscle tissue. The route supports faster absorption compared to subcutaneous administration. The route is used for some peptide preparations per FDA prescribing information and per indication-specific clinical context. IM administration typically occurs in clinic settings with healthcare provider administration.

Intravenous (IV) administration delivers medication directly into the venous system. The route supports immediate availability and precise dose-response control. The route is used in inpatient and clinic-administered contexts for specific peptide therapy indications. Healthcare provider administration of IV peptide therapy occurs in monitored clinical settings supporting infusion management and immediate response to adverse events.

Examples of IV and clinic-administered peptide therapy contexts include some hospital-administered peptide preparations, specific diagnostic peptide preparations (such as macimorelin used for adult-onset growth hormone deficiency diagnostic testing per AACE 2019 framework), and some indication-specific contexts requiring monitored administration. The physician selects the appropriate route per FDA prescribing information and individual clinical context. The framework operates under AMA Code of Medical Ethics 1.1.5 for off-label and compounded prescribing decisions. Specialty coordination supports complex administration contexts.

Physician-directed framework: FDA prescribing information and AMA Code 1.1.5 anchoring

Dosing, route, schedule, and clinical context decisions per individual patient evaluation

For patient-administered subcutaneous injections, the physician or pharmacist provides administration instruction including site selection, injection technique, needle handling, sharps disposal, and rotation principles. The physician monitors for adverse events through clinical follow-up and FDA MedWatch reporting for serious events. The four-stage monitoring cadence applies: baseline week 0, early follow-up week 4 to 8, stabilization month 3, and maintenance month 6 with annual continuation thereafter.

AMA Code of Medical Ethics 1.1.5 framework applies for off-label and compounded prescribing decisions including documented risk-benefit assessment, FDA-approved alternatives considered, monitoring requirements, and patient understanding through informed consent. AMA Code 2.1.1 establishes the broader informed consent framework. PSI provides conceptual education only. Dosing and administration must be determined by a qualified physician evaluating individual patient context. PSI does not provide personalized administration guidance, specific dosing, or self-administration instructions.

Research Suggests

Direction

FDA-approved peptide therapy uses subcutaneous, intramuscular, and intravenous routes per FDA prescribing information. The physician determines all dosing, route, and administration decisions.

Subcutaneous administration is the most common route across FDA-approved peptide drugs. The GLP-1 receptor agonist class and the anabolic osteoporosis peptide class use subcutaneous administration. Intramuscular and intravenous routes apply for specific peptide therapy indications per FDA prescribing information. The physician determines dosing, route, schedule, and clinical context per FDA label for FDA-approved peptides and AMA Code 1.1.5 framework for compounded preparations. The four-stage monitoring cadence (baseline week 0, early follow-up week 4 to 8, stabilization month 3, maintenance month 6 with annual) applies across the class. Adverse event surveillance through FDA MedWatch supports the FDA-approved class. AMA Code of Medical Ethics 1.1.5 framework governs off-label and compounded prescribing decisions including documented risk-benefit assessment and FDA-approved alternatives considered.

Strongest evidence

FDA prescribing information provides the strongest framework for FDA-approved peptide therapy route and dosing decisions.

FDA prescribing information for FDA-approved peptide drugs provides the strongest framework for route, dosing, and schedule decisions. The label reflects Phase 3 trial evidence supporting FDA approval. Examples include Wegovy semaglutide (NDA 215256) with subcutaneous weekly administration, Ozempic semaglutide (NDA 209637) with subcutaneous weekly administration, Zepbound tirzepatide (NDA 217806) with subcutaneous weekly administration, Mounjaro tirzepatide (NDA 215866) with subcutaneous weekly administration, Forteo teriparatide (NDA 021318) with subcutaneous daily administration, Tymlos abaloparatide (NDA 208743) with subcutaneous daily administration, Evenity romosozumab (NDA 761062 with cardiovascular boxed warning) with subcutaneous monthly administration via two injections per dose, Tesamorelin Egrifta (NDA 022505) with subcutaneous daily administration for HIV-associated lipodystrophy, and Vyleesi bremelanotide (NDA 210557) with subcutaneous on-demand administration for HSDD in premenopausal women. Cardiovascular outcomes evidence anchors many of the metabolic class including SELECT 2023 NEJM and SUSTAIN-6 NEJM 2016. Anabolic osteoporosis evidence includes VERT NEJM 2001 (teriparatide) and FRAME NEJM 2016 (romosozumab).

Limitations

Compounded peptide preparations operate outside FDA pre-market approval. Route and dosing decisions for compounded preparations require AMA Code 1.1.5 framework documentation.

Compounded peptide preparations operate under the FDA Compounding Quality Act of 2013 without FDA pre-market approval. Route and dosing decisions for compounded preparations require AMA Code 1.1.5 framework documentation including risk-benefit assessment and FDA-approved alternatives considered. Evidence base for compounded peptide preparations varies substantially across compounds and indications. Some compounded peptides like compounded thymosin alpha-1 operate at L3 human trials evidence tier in international Zadaxin approval contexts. Other compounded peptides operate at L1 to L2 evidence tier with primarily preclinical evidence. PSI provides conceptual education only and does not provide specific dosing, route selection guidance, or self-administration instructions. Dosing and administration must be determined by a qualified physician. Patient-specific clinical context including age, sex, comorbidities, concurrent medications, and pre-existing conditions affects route and dosing decisions. Specialty coordination supports complex contexts.

Assessment

The framework establishes injection route methodology anchored in FDA prescribing information and AMA Code of Medical Ethics 1.1.5.

PSI's reading: peptide therapy injection routes are well-anchored through FDA prescribing information for FDA-approved peptides and AMA Code of Medical Ethics 1.1.5 framework for compounded preparations. Subcutaneous administration is the most common route across the FDA-approved peptide drug class. Intramuscular and intravenous routes apply for specific indications. The physician determines all dosing, route, schedule, and administration decisions per FDA label and individual clinical context. The four-stage monitoring cadence applies across the class. FDA MedWatch surveillance supports ongoing safety signal monitoring. AMA Code 1.1.5 framework provides ethical anchoring for off-label and compounded prescribing decisions. The PSI compound library provides FDA-approved peptide drug class information. The PSI physician directory provides verified physicians applying FDA prescribing information and AMA Code 1.1.5 framework to clinical decisions. Specialty coordination across endocrinology, weight medicine, rheumatology, sports medicine, immunology, infectious disease, women's health, and men's health supports comprehensive evaluation. PSI provides conceptual education only.

How to Approach Your Decision

Limitations and Caveats

This page is conceptual education only. PSI does not provide specific dosing, route selection guidance, or self-administration instructions.
Dosing and administration must be determined by a qualified physician. Patient-specific clinical context affects all decisions.
FDA prescribing information varies by indication. Wegovy and Ozempic use the same molecule (semaglutide) with different labels and dosing.
Compounded peptide preparations operate outside FDA pre-market approval. AMA Code 1.1.5 framework documentation applies.
Patient-specific clinical context affects route and dosing decisions. Age, sex, comorbidities, concurrent medications matter.
Specialty coordination supports complex administration contexts. Endocrinology, weight medicine, rheumatology, sports medicine support contexts.
Self-sourcing of peptide preparations outside physician prescribing operates outside validated clinical practice. Not a legal substitute.
Patient administration instruction must be provided by prescribing physician or pharmacist. PSI does not provide administration instruction.

What's Marketed vs What's Studied

7 common claims, corrected.

“PSI provides specific dosing instructions for peptide therapy.”

PSI provides conceptual education only and does not provide specific dosing, route selection guidance, or self-administration instructions. Dosing and administration must be determined by a qualified physician evaluating individual patient context. PSI does not provide personalized administration guidance.

“Patients can administer at home peptide therapy without physician instruction.”

Patient administration instruction must be provided by the prescribing physician or pharmacist. The instruction includes site selection, injection technique, needle handling, sharps disposal, and rotation principles. Patient administration without physician instruction operates outside the validated clinical practice framework.

“All peptides use the same injection route.”

FDA-approved peptide drugs use three primary routes determined by FDA prescribing information. Subcutaneous is the most common. Intramuscular and intravenous routes apply for specific indications. The route is determined by the FDA label for each peptide drug rather than a single universal route.

“Self-sourcing peptides allows patients to choose their own route and dose.”

Self-sourcing of peptide preparations outside physician prescribing pathways operates outside the validated clinical practice framework. Research-grade peptide products labeled not for human use are not a legal substitute for physician-prescribed FDA-approved or compounded therapy. AMA Code 1.1.5 framework applies for compounded prescribing decisions.

“Compounded peptide preparations follow the same dosing as FDA-approved peptides.”

Compounded peptide preparations operate under AMA Code 1.1.5 framework with physician-determined dosing per documented risk-benefit assessment. The framework requires FDA-approved alternatives considered per indication. Compounded dosing decisions are individualized per patient context.

“Subcutaneous injection always means abdominal injection.”

Subcutaneous administration uses multiple anatomic sites per FDA prescribing information and physician instruction. Site selection and rotation principles are part of physician-provided administration instruction. The specific sites and rotation pattern depend on the peptide drug and individual patient context.

“Adverse events from peptide therapy do not need to be reported.”

Serious adverse events from FDA-approved peptide drugs should be reported through FDA MedWatch. The surveillance framework supports ongoing safety signal monitoring across the FDA-approved peptide drug class. Healthcare providers and patients can submit MedWatch reports.

Common Questions

What injection routes are used for FDA-approved peptide therapy?

FDA-approved peptide therapy uses three primary injection routes: subcutaneous (SC), intramuscular (IM), and intravenous (IV). The specific route is determined by the FDA label for each peptide drug. Subcutaneous is the most common route across the FDA-approved peptide drug class.

Why is subcutaneous the most common route?

Subcutaneous administration delivers medication into the subcutaneous tissue layer with slower absorption compared to intramuscular or intravenous routes. The slower absorption profile suits many peptide drugs designed for sustained pharmacologic effect. The GLP-1 receptor agonist class and anabolic osteoporosis peptide class use subcutaneous administration.

What FDA-approved peptides use subcutaneous administration?

Subcutaneous FDA-approved peptides include semaglutide (Wegovy NDA 215256, Ozempic NDA 209637), tirzepatide (Zepbound NDA 217806, Mounjaro NDA 215866), liraglutide (Saxenda, Victoza), teriparatide (Forteo NDA 021318), abaloparatide (Tymlos NDA 208743), romosozumab (Evenity NDA 761062 with cardiovascular boxed warning), Tesamorelin Egrifta (NDA 022505), and Vyleesi bremelanotide (NDA 210557).

What is the four-stage monitoring cadence?

The four-stage monitoring cadence applies across peptide therapy. Stage 1 baseline at week 0 establishes the foundation. Stage 2 early follow-up at week 4 to 8 tracks tolerability and side effect emergence. Stage 3 stabilization at month 3 captures steady-state response. Stage 4 maintenance at month 6 with annual continuation thereafter applies the full panel re-check.

Does PSI provide specific dosing for peptide therapy?

No. PSI provides conceptual education only and does not provide specific dosing, route selection guidance, or self-administration instructions. Dosing and administration must be determined by a qualified physician evaluating individual patient context. PSI does not provide personalized administration guidance.

Who provides injection administration instruction?

The prescribing physician or pharmacist provides administration instruction for patient-administered subcutaneous injections. The instruction includes site selection, injection technique, needle handling, sharps disposal, and rotation principles. Patient administration instruction is not provided by PSI.

How are compounded peptide preparations administered?

Compounded peptide preparations are administered per the prescribing physician instruction under AMA Code of Medical Ethics 1.1.5 framework. The framework requires documented risk-benefit assessment, FDA-approved alternatives considered, monitoring requirements, and patient understanding through informed consent. Route and dosing decisions are individualized per patient context.

What is AMA Code of Medical Ethics 1.1.5?

AMA Code of Medical Ethics Opinion 1.1.5 (Off-Label and Investigational Use of Pharmaceuticals) governs off-label and compounded prescribing decisions. The framework requires documented risk-benefit assessment for the specific patient context, FDA-approved alternatives considered, monitoring requirements, and patient understanding through informed consent acknowledgment.

Can I administer at home peptide therapy without physician instruction?

No. Patient administration instruction must be provided by the prescribing physician or pharmacist. The instruction includes site selection, injection technique, needle handling, sharps disposal, and rotation principles. Patient administration without physician instruction operates outside the validated clinical practice framework.

What happens during the early follow-up window?

The early follow-up window at week 4 to 8 tracks tolerability and side effect emergence after peptide therapy initiation. For GLP-1 receptor agonists, the window captures gastrointestinal tolerability assessment. The physician evaluates the response and supports any indication-appropriate dose adjustment decisions per FDA prescribing information.

Where can I get peptide therapy administration instruction?

Administration instruction is provided by the prescribing physician or pharmacist. The instruction is individualized per the specific peptide drug, FDA prescribing information, and individual patient context. PSI does not provide administration instruction. The PSI physician directory provides verified physicians with peptide therapy experience.

What insurance coverage applies to injection supplies?

Insurance coverage for injection supplies depends on the specific peptide drug, indication, and insurance plan. FDA-approved peptide drugs may include injection device or supplies coverage with prior authorization. Compounded peptide preparations are typically billed cash. Discuss specific coverage with your prescribing physician and pharmacy.

How is sharps disposal handled?

Sharps disposal must follow local jurisdiction guidelines and prescribing physician or pharmacist instruction. Used needles and syringes are disposed of in FDA-cleared sharps containers. The prescribing physician or pharmacist provides specific sharps disposal instruction. Local pharmacy or healthcare facility may accept sharps containers.

What if I miss a scheduled dose?

Missed dose handling depends on the specific peptide drug and FDA prescribing information. The prescribing physician provides specific guidance for missed doses including timing rules and any catch-up framework. Discuss missed doses with your prescribing physician. PSI does not provide specific missed-dose guidance.

What is FDA MedWatch?

FDA MedWatch is the FDA Safety Information and Adverse Event Reporting Program. The system supports reporting of serious adverse events from FDA-approved drugs including peptide drugs. Healthcare providers and patients can submit MedWatch reports. The system supports ongoing safety signal monitoring across the FDA-approved peptide drug class.

Where can I find a physician for peptide therapy administration instruction?

The PSI physician directory provides verified physicians across major US cities with peptide therapy experience. Verification includes state medical board license verification, ABMS board certification, and AMA Code 1.1.5 documentation practice. Specialty coordination supports indication-specific contexts.

Sourcing Checklist

Obtain peptide therapy through physician prescription only.
Both FDA-approved and compounded peptide therapy require physician prescription. Self-sourcing operates outside the validated clinical practice framework.
Expect prescribing physician to provide individualized administration instruction.
Instruction includes site selection, injection technique, needle handling, sharps disposal, and rotation principles per FDA prescribing information and individual context.
Confirm FDA prescribing information match for FDA-approved peptide drug class.
Wegovy, Ozempic, Zepbound, Mounjaro, Forteo, Tymlos, Evenity, Tesamorelin, Vyleesi each have FDA-specified route and dosing.
Confirm AMA Code 1.1.5 documentation for compounded preparation prescribing.
Documentation includes risk-benefit assessment, FDA-approved alternatives considered, monitoring requirements, and patient understanding.
Expect physician-only dosing, route, schedule, and clinical context decisions.
Patient-specific clinical context affects all decisions. PSI does not provide personalized dosing or administration guidance.
Follow four-stage monitoring cadence: baseline, early follow-up, stabilization, maintenance.
Baseline week 0, early follow-up week 4-8, stabilization month 3, maintenance month 6 with annual continuation.
Report serious adverse events through FDA MedWatch surveillance.
MedWatch supports reporting of serious adverse events for FDA-approved peptide drug class. Healthcare providers and patients can submit reports.
Discuss any administration questions with prescribing physician.
PSI provides conceptual education only. Administration questions including site selection, technique, and missed-dose handling should be directed to prescribing physician.
Expect specialty coordination for indication-specific contexts.
Endocrinology, weight medicine, rheumatology, sports medicine, immunology, infectious disease, women's health, and men's health support indication-appropriate evaluation.

Regulatory Context

FDA prescribing information for FDA-approved peptide drugs updates periodically with new clinical data, post-marketing surveillance findings, and label changes. New FDA peptide approvals expand the FDA-approved class. FDA MedWatch surveillance supports ongoing safety signal monitoring. AMA Code of Medical Ethics 1.1.5 and 2.1.1 frameworks remain foundational. PSI tracks FDA prescribing information changes and FDA MedWatch safety signals per the Editorial Standards review cadence.

Comparison

Route	Common Application	FDA-Approved Examples	Administration Setting
Subcutaneous (SC)	Most common across FDA-approved peptide class	Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Forteo, Tymlos, Tesamorelin	Patient administration with physician/pharmacist instruction
SC (with two injections per dose)	Anabolic sclerostin antibody framework	Evenity romosozumab (with CV boxed warning)	Clinic-administered or patient-administered per FDA label
SC (on-demand)	HSDD framework	Vyleesi bremelanotide for HSDD in premenopausal women	Patient administration with physician instruction
Intramuscular (IM)	Indication-specific FDA-approved contexts	Per FDA prescribing information per indication	Clinic-administered typically
Intravenous (IV)	Inpatient and clinic-administered contexts	Per FDA prescribing information per indication	Healthcare provider administration in monitored settings
Diagnostic peptide IV	Adult-onset GHD diagnostic testing	Macimorelin per AACE 2019 framework	Clinic-administered with monitoring
Compounded preparation	AMA Code 1.1.5 framework	Per physician documentation framework	Per physician instruction per individualized context
Research-grade self-sourcing	Outside validated clinical practice framework	Not a legal substitute for prescribed therapy	Not appropriate clinical setting

Who This Applies To

· Patient considering FDA-approved peptide therapy and seeking conceptual education on injection routes.
· Adult new to peptide therapy seeking framework orientation before consultation with prescribing physician.
· Patient considering GLP-1 receptor agonist therapy and reviewing subcutaneous administration framework.
· Adult considering anabolic osteoporosis peptide therapy and reviewing subcutaneous administration framework.
· Patient considering compounded peptide therapy and reviewing AMA Code 1.1.5 framework context.
· Adult reviewing the four-stage monitoring cadence framework before peptide therapy initiation.
· Patient seeking to understand FDA-approved peptide drug route diversity across the class.
· Adult considering specialty coordination needs for indication-specific peptide therapy.
· Patient reviewing FDA MedWatch surveillance framework for adverse event reporting context.
· Adult considering off-label compounded preparation and reviewing physician documentation requirements.

Verdict

FDA-approved peptide therapy uses subcutaneous, intramuscular, and intravenous routes per FDA prescribing information. Subcutaneous is the most common. The physician determines all dosing, route, schedule, and clinical context per FDA label for FDA-approved peptides and AMA Code 1.1.5 framework for compounded preparations. The four-stage monitoring cadence applies across the class. PSI provides conceptual education only. Dosing and administration must be determined by a qualified physician. Patient administration instruction is provided by prescribing physician or pharmacist.

In Plain Terms

FDA-approved peptide drugs use three main injection routes. Subcutaneous goes under the skin. Intramuscular goes into muscle. Intravenous goes into a vein. Most FDA-approved peptides use subcutaneous. Examples include Wegovy, Ozempic, Forteo, and others. Your doctor decides which route, dose, and schedule based on the FDA label and your situation. Your doctor or pharmacist shows you how to do self-injections if needed. PSI does not give specific dosing or injection instructions. Always work with your prescribing physician.

Peptide drugs are given by injection. The three main types are under the skin (subcutaneous), into muscle (intramuscular), or into a vein (intravenous). Under the skin is most common for FDA-approved peptides. Your doctor decides which type and how much based on the FDA label and your situation. Your doctor or pharmacist teaches you how to do self-injections if your peptide is meant for home use.

Peptide therapy administration requires physician-determined dosing, route, schedule, and clinical context per FDA prescribing information for FDA-approved peptides and AMA Code 1.1.5 framework for compounded preparations. The PSI physician directory provides verified physicians with peptide therapy experience supporting individualized administration instruction across endocrinology, weight medicine, rheumatology, sports medicine, immunology, infectious disease, women's health, and men's health.

Find a verified physician

PSI's directory only lists physicians who have passed a five-gate verification process: state board active, no disciplinary actions, peptide-category competency, transparent pricing, and patient outcome documentation.

Browse the directory Learn about the verification process →

Related Conditions

Related Education

Featured Compounds

Common Contexts

· Patient considering FDA-approved peptide therapy seeking conceptual route education
· Adult new to peptide therapy seeking framework before physician consultation
· Patient considering GLP-1 receptor agonist and reviewing subcutaneous framework
· Adult considering anabolic osteoporosis peptide and reviewing subcutaneous framework
· Patient considering compounded peptide and reviewing AMA Code 1.1.5 framework
· Adult reviewing four-stage monitoring cadence framework
· Patient understanding FDA-approved peptide drug route diversity
· Adult considering specialty coordination needs
· Patient reviewing FDA MedWatch surveillance framework
· Adult considering off-label compounded preparation documentation requirements

Important Context

This page is educational and does not constitute medical advice. The information presented reflects FDA prescribing information for FDA-approved peptide drugs (Wegovy NDA 215256, Ozempic NDA 209637, Zepbound NDA 217806, Mounjaro NDA 215866, Forteo NDA 021318, Tymlos NDA 208743, Evenity NDA 761062 with cardiovascular boxed warning, Tesamorelin Egrifta NDA 022505, Vyleesi NDA 210557), AMA Code of Medical Ethics 1.1.5 (Off-Label and Investigational Use of Pharmaceuticals) and 2.1.1 (Informed Consent) frameworks, FDA Compounding Quality Act of 2013, and cardiovascular outcomes trial evidence including SELECT 2023, SUSTAIN-6, VERT, and FRAME. This page provides conceptual education only and does not provide specific dosing or self-administration instructions.

Your physician will determine the appropriate peptide therapy dose, route, schedule, and clinical context per FDA prescribing information for FDA-approved peptides and AMA Code 1.1.5 framework for compounded preparations. The framework described here is general and does not substitute for individualized clinical judgment. Specialty coordination supports complex contexts across primary care, endocrinology, weight medicine, rheumatology, sports medicine, immunology, infectious disease, women's health, and men's health.

Patient administration of peptide therapy without prescribing physician instruction and clinical oversight is not appropriate. The prescribing physician or pharmacist provides administration instruction for patient-administered subcutaneous injections including site selection, injection technique, needle handling, sharps disposal, and rotation principles. Self-sourcing of peptide preparations outside physician prescribing pathways operates outside the validated clinical practice framework. Research-grade peptide products labeled not for human use are not a legal substitute for physician-prescribed FDA-approved or compounded therapy.

Educational content only. This page provides conceptual education about FDA-approved peptide therapy injection routes. PSI does not provide specific dosing, route selection guidance, or self-administration instructions. Dosing should be determined by a qualified physician who can evaluate your individual situation. PSI does not provide personalized clinical recommendations. Discuss with your physician before initiating any peptide therapy.

Sources and Citations

[1] FDA Prescribing Information: Wegovy (semaglutide) injection · 2024 · FDA NDA 215256 · Source
[2] FDA Prescribing Information: Ozempic (semaglutide) injection · 2024 · FDA NDA 209637 · Source
[3] FDA Prescribing Information: Zepbound (tirzepatide) injection · 2024 · FDA NDA 217806 · Source
[4] FDA Prescribing Information: Mounjaro (tirzepatide) injection · 2024 · FDA NDA 215866 · Source
[5] FDA Prescribing Information: Forteo (teriparatide) injection · 2020 · FDA NDA 021318 · Source
[6] FDA Prescribing Information: Evenity (romosozumab-aqqg) injection with cardiovascular boxed warning · 2019 · FDA NDA 761062 · Source
[7] FDA Prescribing Information: Egrifta (tesamorelin) for HIV-associated lipodystrophy · 2023 · FDA NDA 022505 · Source
[8] Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial) · New England Journal of Medicine · 2023 · DOI
[9] Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis (VERT trial) · New England Journal of Medicine · 2001 · DOI
[10] American Diabetes Association. Standards of Care in Diabetes 2024 · Diabetes Care · 2024 · DOI
[11] AMA Code of Medical Ethics Opinion 1.1.5: Off-label and Investigational Use of Pharmaceuticals · American Medical Association · 2024 · Source
[12] FDA MedWatch: FDA Safety Information and Adverse Event Reporting Program · US Food and Drug Administration · 2024 · Source

Medical Disclaimer

This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.